Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Baltimore, Maryland 21225


Purpose:

This study will look at the skin accumulation of vildagliptin and its two major metabolites, LAY151 and LAF237-O-Glucuronide, after vildagliptin 50 mg given orally twice a day for 10 days in both healthy volunteers and patients with type 2 diabetes.


Criteria:

Inclusion Criteria: - Healthy volunteers and patients with type 2 diabetes - Non-smoking, Caucasian and African American, male and female (postmenopausal, surgically sterile or using double-barrier method of contraception) subjects between 30 and 65 years of age (inclusive) - Type 2 diabetics on metformin and/or sufonylurea Exclusion Criteria: - History of type 1 diabetes or insulin use - History of coagulation abnormalities - History of abnormal heart conditions - Pregnancy or breastfeeding Other protocol-defined inclusion/exclusion criteria may apply


NCT ID:

NCT00633997


Primary Contact:

Principal Investigator
Novartis
Novartis investigator site


Backup Contact:

N/A


Location Contact:

Baltimore, Maryland 21225
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: January 20, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.